Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-b1a or glatiramer acetate compared with untreated patients

Abstract

The mechanisms behind the beneficial effects of interferon-b1a (IFN-b1a) and glatiramer acetate (GA) in the treatment of multiple sclerosis (MS) are still uncertain. A ltered cytokine patterns have been suggested including inhibition of proinflammatory cytokines like interferon-g (IFN-g) and enhancement of anti-inflammato ry cytokines such as interleukin-4 (IL-4). Twenty-nine patients with MS (10 untreated, nine treated with IFN-b1a and 10 with GA) were investigated with elispot of peripheral blood mononuclear cells. Spontaneous and myelin induced (myelin basic protein (MBP), myelin oligodendro cyte glycoprotein (MO G)-14-39 and MO G 63-87) IFN-g, IL-4, IL-5 and IL-10 secretion was studied. We found a significant reduction of spontaneous IFN-g, IL-4 and IL-5, but no difference in IL-10 secreting cells in both groups of treated patients compared with the untreated patients. Myelin-specific responses showed a significant decrease of IFN-g and an increase of IL-5, but no change in IL-4 and IL-10 secreting cells in treated compared with untreated patients. Both treatment groups revealed similar cytokine secretion patterns except for a more pronounced decrease of both spontaneous and MO G 14-39 induced IL-4 secretion in the IFN-b1a treated group. Thus, immunological effects of IFN-b1a and G A were similar showing that disease promoting Th1 (IFN-g) cells were reduced while the potentially beneficial Th2 response (IL-4) was maintained.

Keywords

elispot glatiramer acetate interferon-β multiple sclerosis myelin basic protein (MBP)myelin oligodendrocyte glyco protein (MO G)

Get full access to this article

View all access options for this article.

References

Miller A , Shapiro S , Gershtein R , Kinarty A , Rawashdeh H , Honigman S et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation . J Neuroimmunol 1998; 92: 113-121 .

Flechter S , Vardi J , Pollak L , Rabey JM. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up . J Neurol Sci 2002; 197: 51-55 .

Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis . Neurology 2002; 58: S10-S22 .

Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis . Neurology 2002; 58: S3-S9 .

Neuhaus O , Farina C , Yassouridis A , Wiendl H , Then Bergh F , Dose T et al. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells . Proc Natl Acad Sci USA 2000; 97: 7452-7457 .

Neuhaus O , Farina C , Wekerle H , Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis . Neurology 2001; 56: 702-708 .

Romagnani S. T-cell subsets (Th1 versus Th2) . Ann Allergy Asthma Immunol 2000; 85: 9-18 ; quiz 18, 21.

Paludan SR. Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship . Scand J Immunol 1998; 48: 459-468 .

Dahle C , Ekerfelt C , Vrethem M , Samuelsson M , Ernerudh J. T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barre syndrome . J Neurol Sci 1997; 153: 54-60 .

10.

Ekerfelt C , Matthiesen L , Berg G , Ernerudh J. Paternal leukocytes selectively increase secretion of IL-4 in peripheral blood during normal pregnancies: demonstrated by a novel one-way MLC measuring cytokine secretion . Am J Reprod Immunol 1997; 38: 320-326 .

11.

Matthiesen L , Ekerfelt C , Berg G , Ernerudh J. Increased numbers of circulating interferon-gamma- and interleukin-4- secreting cells during normal pregnancy . Am J Reprod Immunol 1998; 39: 362-367 .

12.

Ekerfelt C , Ernerudh J , Jenmalm MC. Detection of spontaneous and antigen-induced human interleukin-4 responses in vitro: comparison of ELISPOT, a novel ELISA and real-time RT-PCR . J Immunol Methods 2002; 260: 55-67 .

13.

Wensky A , Marcondes MC , Lafaille JJ. The role of IFN-gamma in the production of Th2 subpopulations: implications for variable Th2-mediated pathologies in autoimmunity . J Immunol 2001; 167: 3074-3081 .

14.

Groux H , O’Garra A , Bigler M , Rouleau M , Antonenko S , de Vries JE et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis . Nature 1997; 389: 737-742 .

15.

McDonald WI , Compston A , Edan G , Goodkin D , Hartung HP , Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis . Ann Neurol 2001; 50: 121-127 .

16.

Wallström E , Khademi M , Andersson M , Weissert R , Linington C , Olsson T. Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis . Eur J Immunol 1998; 28: 3329-3335 .

17.

Czerkinsky CC , Tarkowski A , Nilsson LA , Ouchterlony O , Nygren H , Gretzer C. Reverse enzyme-linked immunospot assay (RELISPOT) for the detection of cells secreting immunoreactive substances . J Immunol Methods 1984; 72: 489-496 .

18.

Ekerfelt C , Ernerudh J , Bunikis J , Vrethem M , Aagesen J , Roberg M et al. Compartmentalization of antigen specific cytokine responses to the central nervous system in CNS borreliosis: secretion of IFN-gamma predominates over IL-4 secretion in response to outer surface proteins of Lyme disease Borrelia spirochetes . J Neuroimmunol 1997; 79: 155-162 .

19.

Bakhiet M , Ozenci V , Withagen C , Mustafa M , Fredricksson S , Link H. A new cell enzyme-linked immunosorbent assay demonstrates gamma interferon suppression by beta interferon in multiple sclerosis . Clin Diagn Lab Immunol 1999; 6: 415-419 .

20.

Khademi M , Wallström E , Andersson M , Piehl F , DiMarco R , Olsson T. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis . J Neuroimmunol 2000; 103: 202-210 .

21.

Chen M , Gran B , Costello K , Johnson K , Martin R , Dhib-Jalbut S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS . Mult Scler 2001; 7: 209-219 .

22.

Wiesemann E , Sonmez D , Heidenreich F , Windhagen A. Interferon-beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T-cells . J Neuroimmunol 2002; 123: 160-169 .

23.

özenci V , Kouwenhoven M , Huang YM , Xiao B , Kivisäkk P , Fredriksson S et al. Multiple sclerosis: levels of interleukin- 10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment . Scand J Immunol 1999; 49: 554-561 .

24.

özenci V , Kouwenhoven M , Press R , Link H , Huang YM. IL-12 elispot assays to detect and enumerate IL-12 secreting cells . Cytokine 2000; 12: 1218-1224 .

25.

ö zenci V , Kouwenhoven M , Teleshova N , Pashenkov M , Fredriksson S , Link H. Multiple sclerosis: pro- and anti- inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta . J Neuroimmunol 2000; 108: 236-243 .

26.

Andersson M , Khademi M , Wallström E , Olsson T. Cytokine profile in interferon-beta treated multiple sclerosis patients: reduction of interleukin-10 mRNA expressing cells in peripheral blood . Eur J Neurol 1997; 4: 567-571 .